Author:
Hao Lin,Zhang Zhi-Guo,Shi Zheng-Duo,Pang Kun,Zhang Jun-Jie,Dong Yang,Han Cong-Hui
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Biochemistry,General Medicine,Biophysics
Reference10 articles.
1. Hao, L., Shi, Z. D., & Han, C. H. (2009). Anti-tumor effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Progress in Modern Biomedical,
20, 3983–3985.
2. Zoog, S. J., Ma, C. Y., Kaplan-Lefko, P. J., Hawkins, J. M., Moriguchi, J., Zhou, L., et al. (2010). Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry Part A,
77, 849–860.
3. Sanlioglu, A. D., Karacay, B., Koksal, I. T., Griffith, T. S., & Sanlioglu, S. (2007). DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5 hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Therapy,
14, 976–984.
4. Chen, J. Q., Zhu, C. S., Gong, Z. Y., & Zhao, J. H. (2007). Cloning of soluble hTRAIL tumor-specific vector and expression in nasopharyngeal carcinoma cell line CNE-2. Chinese Journal of Otorhinolaryngology-Skull Base Surgery,
13, 407–410.
5. Wang, D., & Shi, L. (2009). High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Applied Biochemistry and Biotechnology,
157, 1–9.